Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts
Jason A Trubiano, Monica A Slavin, Karin A Thursky, M Lindsay Grayson, Elizabeth J Phillips
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | ELSEVIER | Published : 2019
Antibiotic allergies are reported in up to 1 in 4 immunocompromised hosts with significant impacts on antibiotic utilization and patient outcomes. Health services programs focused on de-labeling beta-lactam and sulfonamide allergy labels should be a standard of care in immunocompromised hosts.
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by National Centre for Infections in Cancer, NHMRC, Centre for Research Excellence
Awarded by National Institutes of Health
This work was supported by the Austin Medical Research Foundation.J. A. Trubiano is supported by a National Health and Medical Research Council (NHMRC) postgraduate scholarship (GNT 1139902) and a postgraduate scholarship from the National Centre for Infections in Cancer, NHMRC, Centre for Research Excellence (App 1116876). E. J. Phillips receives grant support from the National Institutes of Health (award nos. 1P50GM115305-01) and the NHMRC. The rest of the authors declare that they have no relevant conflicts of interest.